Clinical Trial

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2017-04-20; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2020-11-09
Trial Details
NCT Number NCT03127267
Lead Sponsor AB Science
Conditions Amyotrophic Lateral Sclerosis
Enrollment 495 participants
Start Date 2021-02-02
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-12